Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07356453 · ClinicalTrials.gov registry record · Phase 1
A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.
A Phase 1 study of Advanced Solid Tumors, sponsored by FoRx Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 8
- Study locations
NCT07356453: Recruiting Phase 1 study of Advanced Solid Tumors, sponsored by FoRx Therapeutics.
NCT07356453 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by FoRx Therapeutics. The registered enrollment target is 40 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (80% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07356453, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by FoRx Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 8
- Study locations
Study Summary
The goal of this interventional study is to evaluate the safety and tolerability of escalating doses of FORX-48 as monotherapy in patients with select advanced solid tumors with BRCA1/2 mutations or other DDR deficiencies or high replication stress, and to determine the maximum tolerated dose (MTD) and Recommended Cohort Expansion Dose (RCED) of FORX-428 as monotherapy.
Conditions Studied
Interventions
- DRUG FORX-428
Study Locations (8)
California
- Stanford University Medical Center - Palo Alto
- University of California, San Francisco - San Francisco
Texas
- University of Texas - MD Anderson Cancer Center - Houston
- START - San Antonio - San Antonio
Michigan
- START - Midwest - Grand Rapids
Missouri
- Washington University St. Louis - St Louis
Oregon
- Knight Cancer Institute - Portland
Virginia
- NEXT - Virginia Cancer Specialists - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-07-22 |
| Est. Completion | 2028-04 |
| Phase | Phase 1 |
What NCT07356453 shows while recruiting
NCT07356453 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which FORX-428 is the first listed.
NCT07356453 lists 8 locations in 6 states (California, Texas, Michigan).
Frequently Asked Questions
What is clinical trial NCT07356453 about?
NCT07356453 is a clinical study titled "A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.". The goal of this interventional study is to evaluate the safety and tolerability of escalating doses of FORX-48 as monotherapy in patients with select advanced solid tumors with BRCA1/2 mutations or other DDR deficiencies or high replication stress, and to determine the maximum tolerated dose (MTD) ...
What is the current status of trial NCT07356453?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2025-07-22. Estimated completion is 2028-04.
What conditions does trial NCT07356453 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT07356453?
The interventions under investigation include: FORX-428 (DRUG).
Who is sponsoring clinical trial NCT07356453?
This trial is sponsored by FoRx Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07356453 being conducted?
This trial has 8 study locations across California, Michigan, Missouri, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07356453's enrollment target sits among peer trials
40 110th of 144 higher than 34 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI